Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Single Ascending Doses of BIIB063 in Healthy Volunteers

17 april 2017 uppdaterad av: Biogen

Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers

The primary objective of the study is to evaluate the safety and tolerability of single ascending intravenous (IV) doses and a single subcutaneous (SC) dose of BIIB063 in healthy volunteers. The secondary objectives of the study are to estimate the PK parameters of single ascending IV doses of BIIB063; to estimate the PK parameters and absolute bioavailability (F) of a single SC dose of BIIB063; and to evaluate the immunogenicity of single ascending doses of BIIB063.

Studieöversikt

Status

Avslutad

Betingelser

Intervention / Behandling

Studietyp

Interventionell

Inskrivning (Faktisk)

29

Fas

  • Fas 1

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • West Yorkshire
      • Leeds, West Yorkshire, Storbritannien, LD2 9LH
        • Research Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 55 år (Vuxen)

Tar emot friska volontärer

Ja

Kön som är behöriga för studier

Allt

Beskrivning

Key Inclusion Criteria:

  • All male subjects and all female subjects of childbearing potential must practice at least 1 highly effective method of contraception (i.e., contraceptive measure with a failure rate of <1% per year; estrogen-containing contraceptives are prohibited) during the study and be willing and able to continue contraception for 4 months after being dosed with study treatment. Male subjects must also be willing to refrain from sperm donation for at least 4 months after the last dose of study treatment. Male subjects must not have unprotected sexual intercourse with a female who is pregnant or breastfeeding during the study.
  • Must have a body mass index between 18 and 30 kg/m2, inclusive.
  • Must be in good health as determined by the Investigator, based on medical history, physical examination, and 12-lead ECG.

Key Exclusion Criteria:

  • History of or positive test result at screening for human immunodeficiency virus, hepatitis C virus antibody, or hepatitis B virus (defined as positive for hepatitis B surface antigen [HBsAg] or hepatitis B core antibody [HBcAb]).
  • History of any clinically significant cardiac, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, or other major disease, as determined by the Investigator.
  • Personal or family history of cardiovascular disease under the age of 50 years, inherited disorder of coagulation (e.g., Factor V Leiden, protein C or S deficiency), or anti-phospholipid Ab syndrome (APS).
  • History of meningococcal vaccination or meningococcal meningitis, or history of hypersensitivity to single components of meningococcal vaccines (including MENVEO), any other CRM197, diphtheria toxoid, or meningococcal-containing vaccine.
  • History of tuberculosis (TB) or positive QuantiFERON®-TB Gold test
  • Personal history of thromboembolic events
  • Treatment with any prescription or over-the-counter medication within 14 days prior to randomization (excluding vitamins, dietary supplements, herbal preparations, progestin-only birth control, and paracetamol up to 4 g/day for no more than 5 consecutive days).
  • Current enrollment or a plan to enroll in any interventional clinical study in which an investigational treatment or approved therapy for investigational use is administered within 3 months
  • Current enrollment or a plan to enroll in any other drug, biologic or device clinical study, or treatment with an investigational drug or approved therapy for investigational use within 3 months
  • Blood donation (1 unit or more) within 3 months prior to randomization.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Fyrdubbla

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: IV Dose 1
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
En dos
Experimentell: IV Dose 2
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
En dos
Experimentell: IV Dose 3
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
En dos
Experimentell: IV Dose 4
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
En dos
Experimentell: IV Dose 5
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
En dos
Experimentell: IV Dose 6
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
En dos
Experimentell: IV Dose 7
Single ascending IV dose or matching placebo based on body weight recorded on Day 1
Single ascending IV dose
En dos
Experimentell: SC Dose
Single SC dose or matching placebo
Single ascending IV dose
En dos

Vad mäter studien?

Primära resultatmått

Resultatmått
Tidsram
Number of participants experiencing Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: Up to week 12
Up to week 12
Number of participants with clinically significant laboratory assessment abnormalities
Tidsram: Up to week 12
Up to week 12
Number of participants with clinically significant Vital sign abnormalities
Tidsram: Up to week 12
Up to week 12
Number of participants with clinically significant 12-lead electrocardiograms (ECGs) abnormalities
Tidsram: Up to week 12
Up to week 12
Number of participants with clinically significant physical examination abnormalities
Tidsram: Up to week 12
Up to week 12
Change in antibody titers of vaccine immunization for tetanus
Tidsram: Up to week 12
Up to week 12
Change in antibody titers of vaccine immunization for diphtheria
Tidsram: Up to week 12
Up to week 12
Change in antibody titers of vaccine immunization for pneumococcus
Tidsram: Up to week 12
Up to week 12

Sekundära resultatmått

Resultatmått
Tidsram
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Tidsram: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Tidsram: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Maximum observed concentration (Cmax)
Tidsram: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Time to reach maximum observed concentration (Tmax)
Tidsram: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Terminal elimination half-life (t1/2)
Tidsram: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Clearance (CL)
Tidsram: Up to week 12
Up to week 12
PK parameter of single-ascending IV doses of BIIB063: Volume of distribution at steady state (Vss)
Tidsram: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to the time of the last measurable sample (AUClast)
Tidsram: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Area under the concentration-time curve from time zero to infinity (AUCinf)
Tidsram: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Maximum observed concentration (Cmax)
Tidsram: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Time to reach maximum observed concentration (Tmax)
Tidsram: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Terminal elimination half-life (t1/2)
Tidsram: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063 Apparent total body clearance (CL/F)
Tidsram: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Apparent volume of distribution during terminal elimination phase (Vz/F)
Tidsram: Up to week 12
Up to week 12
PK parameter of a single SC dose of BIIB063: Absolute Bioavailability (F)
Tidsram: Up to week 12
Up to week 12
Number of participants with positive serum anti-BIIB063 antibodies
Tidsram: Up to week 12
Up to week 12
Percentage of participants with positive anti-BIIB063 titers within 12 weeks after administration of BIIB063
Tidsram: Up to 12 weeks
Up to 12 weeks

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

30 september 2015

Primärt slutförande (Faktisk)

1 juni 2016

Avslutad studie (Faktisk)

1 juni 2016

Studieregistreringsdatum

Först inskickad

27 augusti 2015

Först inskickad som uppfyllde QC-kriterierna

17 september 2015

Första postat (Uppskatta)

21 september 2015

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

18 april 2017

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

17 april 2017

Senast verifierad

1 april 2017

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • 234HV101
  • 2015-001283-18 (EudraCT-nummer)

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera